GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » ROA %

Longeveron (Longeveron) ROA % : -203.45% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Longeveron ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Longeveron's annualized Net Income for the quarter that ended in Dec. 2023 was $-24.11 Mil. Longeveron's average Total Assets over the quarter that ended in Dec. 2023 was $11.85 Mil. Therefore, Longeveron's annualized ROA % for the quarter that ended in Dec. 2023 was -203.45%.

The historical rank and industry rank for Longeveron's ROA % or its related term are showing as below:

LGVN' s ROA % Range Over the Past 10 Years
Min: -118.94   Med: -56.96   Max: -35.26
Current: -118.94

During the past 6 years, Longeveron's highest ROA % was -35.26%. The lowest was -118.94%. And the median was -56.96%.

LGVN's ROA % is ranked worse than
86.63% of 1556 companies
in the Biotechnology industry
Industry Median: -35.515 vs LGVN: -118.94

Longeveron ROA % Historical Data

The historical data trend for Longeveron's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longeveron ROA % Chart

Longeveron Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial -35.26 -37.54 -65.55 -53.68 -108.44

Longeveron Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.55 -75.53 -115.82 -142.24 -203.45

Competitive Comparison of Longeveron's ROA %

For the Biotechnology subindustry, Longeveron's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longeveron's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's ROA % distribution charts can be found below:

* The bar in red indicates where Longeveron's ROA % falls into.



Longeveron ROA % Calculation

Longeveron's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-21.413/( (27.413+12.078)/ 2 )
=-21.413/19.7455
=-108.44 %

Longeveron's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-24.112/( (11.625+12.078)/ 2 )
=-24.112/11.8515
=-203.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Longeveron  (NAS:LGVN) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-24.112/11.8515
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-24.112 / 0.252)*(0.252 / 11.8515)
=Net Margin %*Asset Turnover
=-9568.25 %*0.0213
=-203.45 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Longeveron ROA % Related Terms

Thank you for viewing the detailed overview of Longeveron's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Longeveron (Longeveron) Business Description

Traded in Other Exchanges
N/A
Address
1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136
Longeveron Inc is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida. The company has generated revenue from three sources: 1) Grant awards. 2) The Bahamas Registry Trial. 3) Contract development and manufacturing services.
Executives
Cathy Ross director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Jeffrey Pfeffer director
Lisa Locklear officer: Chief Financial Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova officer: Chief Medical Officer 1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo officer: CFO and Treasurer 1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Hashad Mohamed Wa'el Ahmed officer: Chief Executive Officer SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare director, officer: Chief Scientific Officer C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Kwan-hong Christopher Min officer: Chief Medical Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green officer: CEO 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr officer: General Counsel, Secretary 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer director, 10 percent owner 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136

Longeveron (Longeveron) Headlines

From GuruFocus